Pharmacokinetics of Long-Acting Methylphenidate: Formulation Differences, Bioequivalence, Interchangeability

Area of Science:

• Pharmacokinetics and Drug Formulation
• Neuropsychiatric Disorders
• Regulatory Science

Background:

• Attention deficit hyperactivity disorder (ADHD) is a common childhood neuropsychiatric condition.
• Methylphenidate (MPH) is a first-line ADHD therapy, available in various extended-release (ER) formulations.
• Differences in pharmacokinetics often lead to ER MPH formulations not being considered bioequivalent.

Purpose of the Study:

• Critically review pharmacokinetic data of ER MPH formulations.
• Assess bioequivalence and identify inconsistencies in regulatory guidelines.
• Evaluate pharmacokinetic-pharmacodynamic parameters for defining MPH interchangeability.

Main Methods:

• Conducted a comprehensive literature search in EMBASE, Medline, and Cochrane Library.
• Extracted study characteristics, pharmacokinetic parameters, and bioequivalence data.
• Analyzed direct and indirect comparative studies of ER MPH formulations.

Main Results:

• Thirty-three studies provided primary pharmacokinetic data for ER MPH.
• Two formulations were consistently reported as bioequivalent by regulatory bodies, but inconsistencies were noted.
• Stricter bioequivalence criteria revealed only one formulation met the definition; clinical factors had inconsistent effects.

Conclusions:

• Enhanced pharmacokinetic parameters and standardized regulatory guidelines could improve bioequivalence assessments for ER MPH.
• Further research is necessary to ascertain if bioequivalence is the optimal measure for MPH interchangeability.
• Findings are relevant for formulation scientists, clinical pharmacologists, and clinicians involved in ADHD treatment.